产品名称	DEDN6526A (anti-ETBR)
别名	ABCDS antibody \| Ednra antibody \| EDNRB antibody \| EDNRB_HUMAN antibody \| Endothelin B receptor antibody \| Endothelin B receptor precursor antibody \| Endothelin receptor Non selective type antibody \| Endothelin receptor non-selective type antibody \| Endot
英文别名	Endothelin receptor non-selective type \| ET-B \| ET-BR
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	EDNRB
种属反应性	人(Human)
偶联	Unconjugated

AI解读

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	26.6kDa (Light Chain) & 50.0 kDa (Heavy Chain), under reducing conditions; 189.2kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
分子类型	抗体

图片

SEC: DEDN6526A (anti-ETBR) (Ab177883)

DEDN6526A (anti-ETBR) (Ab177883) - SEC
The purity of DEDN6526A (anti-ETBR) (Ab177883) is more than 95% verified by HPLC.

关联靶点（人）

EDNRB Tclin 内皮素受体B型(Endothelin receptor type B) (0 活性数据)

点击查看靶蛋白信息： EDNRB

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

EDNRB Tclin Endothelin receptor ET-B (1928 活性数据)

点击查看靶蛋白信息： EDNRB

活性类型	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F0506357	分析证书	24-05-31	Ab177883
ZJ24F0506356	分析证书	24-05-31	Ab177883
ZJ24F0506355	分析证书	24-05-31	Ab177883

参考文献

1. Cutshall NS, Ursino R, Kucera KA, Latham J, Ihle NC.. (2001) Nicotinamide N-oxides as CXCR2 antagonists.. Bioorg Med Chem Lett, 11 (14): (1951-1954). [PMID:11459668] [10.1016/s0960-894x(01)00326-2]
2. Patt WC, Cheng XM, Repine JT, Lee C, Reisdorph BR, Massa MA, Doherty AM, Welch KM, Bryant JW, Flynn MA, Walker DM, Schroeder RL, Haleen SJ, Keiser JA.. (1999) Butenolide endothelin antagonists with improved aqueous solubility.. J Med Chem, 42 (12): (2162-2168). [PMID:10377221] [10.1021/jm980504w]
3. Wu C, Decker ER, Blok N, Li J, Bourgoyne AR, Bui H, Keller KM, Knowles V, Li W, Stavros FD, Holland GW, Brock TA, Dixon RA.. (2001) Acyl substitution at the ortho position of anilides enhances oral bioavailability of thiophene sulfonamides: TBC3214, an ETA selective endothelin antagonist.. J Med Chem, 44 (8): (1211-1216). [PMID:11312921] [10.1021/jm000349x]
4. Kondo S, Morita T, Tashima Y. (1994) Endothelin receptor density in human hypertrophic and non-hypertrophic prostate tissue.. Tohoku J Exp Med, 172 (4): (381-4). [PMID:7524189] [10.1021/op500134e]
5. Sakamoto A, Yanagisawa M, Sakurai T, Takuwa Y, Yanagisawa H, Masaki T. (1991) Cloning and functional expression of human cDNA for the ETB endothelin receptor.. Biochem Biophys Res Commun, 178 (2): (656-63). [PMID:1713452] [10.1021/op500134e]
6. Puffenberger EG, Hosoda K, Washington SS, Nakao K, deWit D, Yanagisawa M, Chakravart A. (1994) A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease.. Cell, 79 (7): (1257-66). [PMID:8001158] [10.1021/op500134e]
7. Harland SP, Kuc RE, Pickard JD, Davenport AP. (1995) Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas.. J Cardiovasc Pharmacol, 26 Suppl 3 (13): (S408-11). [PMID:8587429] [10.1021/op500134e]
8. Yamaji T, Fukuhara T, Kinoshita M. (1993) Increased capillary permeability to albumin in diabetic rat myocardium.. Circ Res, 72 (5): (947-57). [PMID:8477528] [10.1021/op500134e]
9. Bolli MH, Marfurt J, Grisostomi C, Boss C, Binkert C, Hess P, Treiber A, Thorin E, Morrison K, Buchmann S et al.. (2004) Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.. J Med Chem, 47 (11): (2776-95). [PMID:15139756] [10.1021/op500134e]
10. Wang Y, Jiao X, Kayser F, Liu J, Wang Z, Wanska M, Greenberg J, Weiszmann J, Ge H, Tian H et al.. (2010) The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators.. Bioorg Med Chem Lett, 20 (2): (493-8). [PMID:20005104] [10.1021/op500134e]
11. Cappelli A, Manini M, Valenti S, Castriconi F, Giuliani G, Anzini M, Brogi S, Butini S, Gemma S, Campiani G et al.. (2013) Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.. Eur J Med Chem, 63 (13): (85-94). [PMID:23466604] [10.1021/op500134e]
12. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR et al.. (2008) cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.. J Med Chem, 51 (22): (7094-8). [PMID:18983139] [10.1021/op500134e]
13. Coombs TC, Tanega C, Shen M, Wang JL, Auld DS, Gerritz SW, Schoenen FJ, Thomas CJ, Aubé J. (2013) Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.. Bioorg Med Chem Lett, 23 (12): (3654-61). [PMID:23642479] [10.1021/op500134e]
14. Migliore M, Habrant D, Sasso O, Albani C, Bertozzi SM, Armirotti A, Piomelli D, Scarpelli R. (2016) Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.. Eur J Med Chem, 109 (13): (216-37). [PMID:26774927] [10.1021/op500134e]
15. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S et al.. (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.. J Pharmacol Exp Ther, 327 (3): (736-45). [PMID:18780830] [10.1021/op500134e]
16. Shihoya W, Nishizawa T, Yamashita K, Inoue A, Hirata K, Kadji FMN, Okuta A, Tani K, Aoki J, Fujiyoshi Y et al.. (2017) X-ray structures of endothelin ET_B receptor bound to clinical antagonist bosentan and its analog.. Nat Struct Mol Biol, 24 (9): (758-764). [PMID:28805809] [10.1021/op500134e]
17. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J et al.. (2010) Spiroindolones, a potent compound class for the treatment of malaria.. Science, 329 (5996): (1175-80). [PMID:20813948] [10.1021/op500134e]
18. Angst D, Gessier F, Janser P, Vulpetti A, Wälchli R, Beerli C, Littlewood-Evans A, Dawson J, Nuesslein-Hildesheim B, Wieczorek G et al.. (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.. J Med Chem, 63 (10): (5102-5118). [PMID:32083858] [10.1021/op500134e]
19. Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, Wehn PM, Yang H, Dixon DD et al.. (2019) 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.. J Med Chem, 62 (15): (6876-6893). [PMID:31282155] [10.1021/op500134e]
20. Wu C, Decker ER, Blok N, Bui H, You TJ, Wang J, Bourgoyne AR, Knowles V, Berens KL, Holland GW, Brock TA, Dixon RA.. (2004) Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.. J Med Chem, 47 (8): (1969-1986). [PMID:15055997] [10.1021/jm030528p]
21. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S.. (2006) An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.. J Med Chem, 49 (11): (3116-3135). [PMID:16722631] [10.1021/jm0508641]
22. Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB.. (2012) ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.. J Med Chem, 55 (1): (515-527). [PMID:22191331] [10.1021/jm2014277]
23. Annedi SC, Maddaford SP, Ramnauth J, Renton P, Rybak T, Silverman S, Rakhit S, Mladenova G, Dove P, Andrews JS, Zhang D, Porreca F.. (2012) Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine.. Eur J Med Chem, 55 (94-107). [PMID:22840695] [10.1016/j.ejmech.2012.07.006]
24. Germain AR, Carmody LC, Nag PP, Morgan B, Verplank L, Fernandez C, Donckele E, Feng Y, Perez JR, Dandapani S, Palmer M, Lander ES, Gupta PB, Schreiber SL, Munoz B.. (2013) Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.. Bioorg Med Chem Lett, 23 (6): (1834-1838). [PMID:23403082] [10.1016/j.bmcl.2013.01.025]
25. Schroeder CE, Yao T, Sotsky J, Smith RA, Roy S, Chu YK, Guo H, Tower NA, Noah JW, McKellip S, Sosa M, Rasmussen L, Smith LH, White EL, Aubé J, Jonsson CB, Chung D, Golden JE.. (2014) Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus.. J Med Chem, 57 (20): (8608-8621). [PMID:25244572] [10.1021/jm501203v]
26. Takai K, Inoue Y, Konishi Y, Suwa A, Uruno Y, Matsuda H, Nakako T, Sakai M, Nishikawa H, Hashimoto G, Enomoto T, Kitamura A, Uematsu Y, Kiyoshi A, Sumiyoshi T.. (2014) Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists.. Bioorg Med Chem Lett, 24 (14): (3189-3193). [PMID:24856064] [10.1016/j.bmcl.2014.04.085]
27. Lopez-Tapia F, Walker KA, Brotherton-Pleiss C, Caroon J, Nitzan D, Lowrie L, Gleason S, Zhao SH, Berger J, Cockayne D, Phippard D, Suttmann R, Fitch WL, Bourdet D, Rege P, Huang X, Broadbent S, Dvorak C, Zhu J, Wagner P, Padilla F, Loe B, Jahangir A, Alker A.. (2015) Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.. J Med Chem, 58 (21): (8413-8426). [PMID:26460788] [10.1021/acs.jmedchem.5b00365]
28. Waszkielewicz AM, Gunia-Krzyżak A, Powroźnik B, Słoczyńska K, Pękala E, Walczak M, Bednarski M, Żesławska E, Nitek W, Marona H.. (2016) Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.. Bioorg Med Chem, 24 (8): (1793-1810). [PMID:26988801] [10.1016/j.bmc.2016.03.006]
29. Lepri S, Goracci L, Valeri A, Cruciani G.. (2016) Metabolism study and biological evaluation of bosentan derivatives.. Eur J Med Chem, 121 (658-670). [PMID:27318985] [10.1016/j.ejmech.2016.06.006]
30. Khadtare N, Stephani R, Korlipara V.. (2017) Design, synthesis and evaluation of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives as ETA receptor selective antagonists using FRET assay.. Bioorg Med Chem Lett, 27 (11): (2281-2285). [PMID:28462837] [10.1016/j.bmcl.2017.04.049]
31. Boss C, Bolli MH, Gatfield J.. (2016) From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.. Bioorg Med Chem Lett, 26 (15): (3381-3394). [PMID:27321813] [10.1016/j.bmcl.2016.06.014]
32. Aubert JD, Juillerat-Jeanneret L.. (2016) Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.. J Med Chem, 59 (18): (8168-8188). [PMID:27266371] [10.1021/acs.jmedchem.5b01781]
33. Xu F,Zhao Y,Zhou H,Li C,Zhang X,Hou T,Qu L,Wei L,Wang J,Liu Y,Liang X. (2020) Synthesis and evaluation of 3-(4-(phenoxymethyl)phenyl)propanoic acid and N-phenylbenzenesulfonamide derivatives as FFA4 agonists.. Bioorg Med Chem Lett, 30 (24): (127650-127650). [PMID:33127539] [10.1016/j.bmcl.2020.127650]
34. Richard, V V and 5 more authors.. (1994) Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist.. British journal of pharmacology, [PMID:7858879]
35. Hofstra, R M RM and 11 more authors.. (1996) A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome).. Nature genetics, [PMID:8630503]
36. Auricchio, A A, Casari, G G, Staiano, A A and Ballabio, A A.. (1996) Endothelin-B receptor mutations in patients with isolated Hirschsprung disease from a non-inbred population.. Human molecular genetics, [PMID:8852659]
37. Amiel, J J and 12 more authors.. (1996) Heterozygous endothelin receptor B (EDNRB) mutations in isolated Hirschsprung disease.. Human molecular genetics, [PMID:8852660]
38. Bourgeois, C C and 6 more authors.. (1997) Endothelin-1 and ETA receptor expression in vascular smooth muscle cells from human placenta: a new ETA receptor messenger ribonucleic acid is generated by alternative splicing of exon 3.. The Journal of clinical endocrinology and metabolism, [PMID:9284755]
39. Hofstra, R M RM, Osinga, J J and Buys, C H CH.. Mutations in Hirschsprung disease: when does a mutation contribute to the phenotype.. European journal of human genetics : EJHG, [PMID:9359036]
40. Svensson, P J PJ, Anvret, M M, Molander, M L ML and Nordenskjöld, A A.. (1998) Phenotypic variation in a family with mutations in two Hirschsprung-related genes (RET and endothelin receptor B).. Human genetics, [PMID:9760196]
41. Brooks, A S AS and 7 more authors.. (1999) A consanguineous family with Hirschsprung disease, microcephaly, and mental retardation (Goldberg-Shprintzen syndrome).. Journal of medical genetics, [PMID:10874640]
42. Fuchs, S S and 5 more authors.. (2001) Functional characterization of three mutations of the endothelin B receptor gene in patients with Hirschsprung's disease: evidence for selective loss of Gi coupling.. Molecular medicine (Cambridge, Mass.), [PMID:11471546]
43. Verheij, Joke B G M JB, Kunze, Jürgen J, Osinga, Jan J, van Essen, Anthonie J AJ and Hofstra, Robert M W RM.. (2002) ABCD syndrome is caused by a homozygous mutation in the EDNRB gene.. American journal of medical genetics, (15): [PMID:11891690]
44. Pingault, Véronique V and 9 more authors.. (2002) SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism.. Human genetics, [PMID:12189494]
45. Zaahl, M G MG, du Plessis, L L, Warnich, L L, Kotze, M J MJ and Moore, S W SW.. (2003) Significance of novel endothelin-B receptor gene polymorphisms in Hirschsprung's disease: predominance of a novel variant (561C/T) in patients with co-existing Down's syndrome.. Molecular and cellular probes, [PMID:12628594]
46. Dunham, A A and 125 more authors.. (2004) The DNA sequence and analysis of human chromosome 13.. Nature, (1): [PMID:15057823]
47. Urbanowicz, W W and 9 more authors.. (2004) Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats.. Gut, [PMID:15542526]
48. Said, Shehta A SA, Ammar, El Sayed M el SM and Suddek, Ghada M GM.. (2005) Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes.. Pharmacological research, [PMID:15629255]
49. Motte, Sophie S, McEntee, Kathleen K and Naeije, Robert R.. (2006) Endothelin receptor antagonists.. Pharmacology & therapeutics, [PMID:16219361]
50. Gupta, Suresh K SK, Saxena, Amit A, Singh, Uma U and Arya, Dharamvir S DS.. (2005) Bosentan, the mixed ETA-ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion.. Molecular and cellular biochemistry, [PMID:16335785]
51. Kingman, Martha M, Ruggiero, Rosechelle R and Torres, Fernando F.. (2009) Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.. Expert opinion on pharmacotherapy, [PMID:19601701]
52. Casserly, Brian B and Klinger, James R JR.. (2009) Ambrisentan for the treatment of pulmonary arterial hypertension.. Drug design, development and therapy, (6): [PMID:19920913]
53. Issa, Sarah S and 13 more authors.. (2017) EDNRB mutations cause Waardenburg syndrome type II in the heterozygous state.. Human mutation, [PMID:28236341]
54. Thenappan, Thenappan; Ormiston, Mark L; Ryan, John J and Archer, Stephen L.. (2018) Pulmonary arterial hypertension: pathogenesis and clinical management.. BMJ (Clinical research ed.), (14): [PMID:29540357]
55. Bedan, Martin and 5 more authors.. (2018) A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.. Basic & clinical pharmacology & toxicology, [PMID:29719121]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

DEDN6526A (anti-ETBR)

库存信息

库存信息

库存信息

库存信息

基本信息

AI解读

产品属性

图片

关联靶点（人）

作用机制

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关文档

相关产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器